GLP-1 agonists produce rapid weight loss, but they don't discriminate between fat and muscle. Competitors on semaglutide or tirzepatide report strength drops alongside the scale , and some are reaching for growth hormone secretagogues to preserve lean tissue.
Tesamorelin is the most common pick. Originally studied for HIV-associated lipodystrophy, it's a synthetic analog of growth hormone-releasing hormone (GHRH). It increases endogenous GH pulses without shutting down the pituitary. One competitor mentioned running it alongside tirzepatide during a cut and "feeling less flat" in the gym, though anecdotal reports don't replace controlled data.
This article discusses peptides as research compounds. It is not medical advice.
Why Stack a GH Secretagogue with a GLP-1?
GLP-1 receptor agonists slow gastric emptying and reduce appetite. Weight drops fast. But calorie restriction plus GLP-1 signaling can accelerate muscle catabolism, especially in a deficit large enough to trigger adaptive thermogenesis.
Growth hormone secretagogues theoretically counteract this by:
- Elevating serum GH, which promotes lipolysis and nitrogen retention
- Increasing IGF-1, which signals muscle protein synthesis
- Shifting substrate utilization toward fat oxidation
Except , and this matters , no published trial has tested tesamorelin specifically in combination with semaglutide or tirzepatide. The rationale is mechanistic, not clinical.
Tesamorelin: Mechanism and Dosing in Studies
Tesamorelin is a 44-amino-acid peptide that binds GHRH receptors in the anterior pituitary. It triggers GH release in a pulsatile pattern that mimics endogenous secretion. Serum GH peaks 30-60 minutes post-injection, then returns to baseline within a few hours.
In the two pivotal trials for visceral adiposity reduction (published in The Lancet, 2010), participants received 2 mg subcutaneously once daily. Visceral adipose tissue decreased by roughly 15% over 26 weeks, with modest increases in IGF-1 and no sustained elevation in fasting glucose.
Key findings from those studies:
- Mean VAT reduction: -15.2% vs. -1.8% placebo
- Lean body mass: no significant change in either group
- IGF-1: increased by ~80 ng/mL on average
- Adverse events: injection-site reactions, transient hyperglycemia in a subset
Tesamorelin does not appear to build muscle outright. It may help preserve existing lean mass during caloric restriction, but the HIV lipodystrophy trials were not designed to measure that outcome.
IGF-1 LR3: A More Aggressive Option
IGF-1 Long R3 is a synthetic analog of insulin-like growth factor-1 with reduced affinity for IGF-binding proteins. That means longer half-life and higher bioavailability. It's not FDA-approved for any indication and exists solely as a research reagent.
Powerlifters and bodybuilders report using it to prevent muscle loss during aggressive cuts. Dosing protocols mentioned in community forums range from 40 to 100 mcg per day, injected subcutaneously or intramuscularly, often split bilaterally into muscle groups being trained.
But IGF-1 LR3 carries more risk than tesamorelin:
- Hypoglycemia, especially when fasted or training glycogen-depleted
- Potential for organ hypertrophy with chronic use (no long-term human data)
- No published safety trials in healthy adults
One competitor mentioned stacking 50 mcg IGF-1 LR3 with 1 mg semaglutide weekly and reported "holding strength better than expected," but also noted blood sugar crashes mid-session. Anecdotes like that don't establish safety or efficacy.
Head-to-Head: Tesamorelin vs. IGF-1 LR3
No study has directly compared these two compounds. Tesamorelin works upstream (pituitary GH release), while IGF-1 LR3 works downstream (direct IGF-1 receptor agonism). They're not interchangeable.
Here's how they differ in practice:
- Mechanism
- Tesamorelin: stimulates endogenous GH pulses. IGF-1 LR3: exogenous IGF-1 analog, bypasses GH entirely.
- Half-life
- Tesamorelin: ~30 minutes for GH peak, effects dissipate within hours. IGF-1 LR3: ~20-30 hours, sustained receptor activation.
- Safety data
- Tesamorelin: two Phase III trials, FDA-approved for lipodystrophy. IGF-1 LR3: no human trials, research-grade only.
- Glycemic impact
- Tesamorelin: transient hyperglycemia in some users. IGF-1 LR3: hypoglycemia risk, especially fasted.
Tesamorelin is the safer bet if you're prioritizing documented outcomes. IGF-1 LR3 is the more direct route to IGF-1 receptor activation, but with zero clinical validation.
Secondary Compounds in GLP-1 Muscle-Retention Stacks
Beyond tesamorelin and IGF-1 LR3, several other peptides appear in muscle-preservation protocols. None have been studied in combination with GLP-1 agonists, but all have proposed mechanisms that could theoretically support lean tissue retention.
MK-677 (Ibutamoren)
MK-677 is an orally active ghrelin mimetic that increases GH and IGF-1. A 2008 study in Journal of Clinical Endocrinology & Metabolism showed it raised IGF-1 by ~40% over two months in healthy older adults. Lean mass increased modestly, fat mass did not change significantly.
Dosing in studies: 25 mg once daily, typically taken before bed to align with natural GH pulses. Side effects included increased appetite and mild edema , the appetite boost can work against GLP-1's anorectic effect.
Ipamorelin
Ipamorelin is a selective ghrelin receptor agonist (growth hormone secretagogue). It stimulates GH release without affecting cortisol or prolactin. Animal models show it increases lean mass and bone density, but human data are sparse.
Community dosing: 200-300 mcg injected two to three times daily. One competitor mentioned pairing it with semaglutide and noted "less muscle flatness" during a 12-week cut, though no formal measurements were taken.
BPC-157
BPC-157 is a pentadecapeptide derived from a gastric protective protein. It's studied primarily for tendon and ligament repair in rodent models. Some users report faster recovery and reduced joint pain during high-volume training blocks, which could indirectly support muscle retention by allowing more training stimulus.
Dosing in animal studies: ~200-400 mcg per kilogram body weight. Human equivalents are speculative. Posters in the BPC-157 thread on r/Peptides noted a similar pattern, though no formal study has tested it (PubMed).
CJC-1295
CJC-1295 is a GHRH analog with an extended half-life (due to Drug Affinity Complex technology). It raises GH and IGF-1 for several days per injection. A 2006 study in healthy adults showed a single 60 mcg/kg dose elevated IGF-1 by ~60% for up to 13 days.
Dosing in community protocols: 1-2 mg once or twice weekly. Often stacked with ipamorelin for a "pulse and sustain" effect. No trials have tested it alongside GLP-1 agonists.
Where Each Compound Is Studied More
Tesamorelin has the most robust human data, all focused on visceral fat reduction in HIV lipodystrophy. The two pivotal trials enrolled over 800 participants combined. IGF-1 LR3 has no published human trials , only in vitro and animal work.
MK-677 has been studied in older adults for sarcopenia prevention and in growth hormone deficiency. Ipamorelin and CJC-1295 have limited human pharmacokinetic data but no large-scale efficacy trials. BPC-157 remains entirely preclinical in terms of peer-reviewed literature.
If you're looking for evidence that any of these compounds preserve muscle during GLP-1-induced weight loss, you won't find it. The hypothesis is mechanistic: GH and IGF-1 promote nitrogen retention and lipolysis, so elevating them should counteract muscle catabolism. But GLP-1 agonists also alter gut hormone signaling, gastric motility, and possibly myokine expression , interactions that haven't been mapped.
Practical Considerations for Stacking Protocols
Competitors experimenting with these stacks report a few consistent patterns:
- Injection timing: Tesamorelin or ipamorelin are typically dosed in the morning or pre-training to align with cortisol and activity. IGF-1 LR3 is often split bilaterally into trained muscle groups.
- Monitoring: Fasting glucose and HbA1c should be tracked if stacking GH secretagogues with GLP-1 agonists, given opposing glycemic effects.
- Training volume: Higher GH/IGF-1 may allow more recovery capacity, but GLP-1-induced appetite suppression can limit energy availability. Protein intake needs deliberate attention.
- Cycle length: Tesamorelin studies ran 26 weeks. Community cycles for IGF-1 LR3 rarely exceed 4-6 weeks due to cost and hypoglycemia risk.
And one more thing: GLP-1 agonists are prescription medications. Tesamorelin is also prescription-only (FDA-approved for Egrifta). IGF-1 LR3, MK-677, and the others exist in a regulatory gray zone. Researchers conducting independent work should follow institutional protocols and ethics review where applicable.
What the Literature Doesn't Tell You
No study has measured lean mass retention in GLP-1 users who add a GH secretagogue. No trial has compared tesamorelin to IGF-1 LR3 in any population. The closest proxy is the HIV lipodystrophy work, which showed tesamorelin reduced visceral fat without changing lean mass , but those participants were not in a caloric deficit or on a GLP-1.
The BPC-157 literature is entirely rodent models. CJC-1295 and ipamorelin have pharmacokinetic data but no efficacy trials in muscle preservation. MK-677 has the most human data outside tesamorelin, but it wasn't tested in combination with anything.
What you're left with is mechanism and anecdote. Both can guide experimentation, but neither replaces controlled evidence. If you're stacking these compounds, you're running an n=1 protocol with unknown interactions and no long-term safety data.